Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
AssigneeSt. Jude Children's Research Hospital
InventorsRichard J. Bram, Gotz Von Bulow
Life of this patent
Estimating the term…
Loading patent…
AssigneeSt. Jude Children's Research Hospital
InventorsRichard J. Bram, Gotz Von Bulow
Estimating the term…
A novel lymphocyte receptor protein, its DNA sequence, and its role in the calcium activation pathway is described. The protein, or genetically engineered constructs encoding it, are shown to increase lymphocyte response, and to identify ligands of the protein receptor. Antibodies to the proteins of the invention are generated for diagnostic therapeutics. The protein and DNA can also be used for diagnostic purposes and for identifying agents for modulating the calcium induced activation pathway. A particular advantage of the present invention is that it provides lymphocyte activation of receptor found on all B cells, but only on a subset of T cells. The receptor can thus be targeted to specifically regulate B cell responses without affecting mature T cell activity. Such targeting specificity is always advantageous, particularly where an increase or decrease of antibody production is desired, e.g., during an infection (increase) or to avoid immune complex deposition complications (rheumatoid arthritis, glomerulonephritis, and other auto immune conditions).
An isolated Transmembrane Activator and CAML Interactor (TACI) protein that functions as a cell surface signaling protein comprising an extracellular domain, a membrane spanning segment, and a cytoplasmic domain that has a binding affinity for CAML, wherein said TACI protein is a plasma membrane receptor that interacts directly with an intracellular organelle in lymphocytes.
An isolated polypeptide encoded by a nucleic acid consisting of at least 18 consecutive nucleotides of a nucleotide sequence, wherein said nucleotide sequence encodes a Transmembrane Activator and CAML Interactor (TACI) protein having the amino acid sequence of SEQ ID NO:2;
A proteolytic fragment of an isolated Transmembrane Activator and CAML Interactor (TACI) protein;
An isolated polypeptide comprising an N-terminal fragment of a Transmembrane Activator and CAML Interactor (TACI) protein;
An isolated polypeptide comprising a C-terminal fragment of a Transmembrane Activator and CAML Interactor (TACI) protein;
Dependencies are inferred from the claim text.